Arrowhead Pharmaceuticals (ARWR) EBIAT (2016 - 2025)
Historic EBIAT for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $30.8 million.
- Arrowhead Pharmaceuticals' EBIAT rose 11758.44% to $30.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $230.6 million, marking a year-over-year increase of 13550.22%. This contributed to the annual value of $30.1 million for FY2025, which is 10493.92% up from last year.
- Latest data reveals that Arrowhead Pharmaceuticals reported EBIAT of $30.8 million as of Q4 2025, which was up 11758.44% from $8.0 million recorded in Q3 2025.
- Arrowhead Pharmaceuticals' EBIAT's 5-year high stood at $370.4 million during Q1 2025, with a 5-year trough of -$178.7 million in Q2 2025.
- Moreover, its 5-year median value for EBIAT was -$67.7 million (2021), whereas its average is -$53.0 million.
- Per our database at Business Quant, Arrowhead Pharmaceuticals' EBIAT plummeted by 36090.6% in 2024 and then surged by 39169.82% in 2025.
- Arrowhead Pharmaceuticals' EBIAT (Quarter) stood at -$62.9 million in 2021, then skyrocketed by 33.5% to -$41.8 million in 2022, then plummeted by 223.78% to -$135.4 million in 2023, then dropped by 29.43% to -$175.2 million in 2024, then skyrocketed by 117.58% to $30.8 million in 2025.
- Its EBIAT was $30.8 million in Q4 2025, compared to $8.0 million in Q3 2025 and -$178.7 million in Q2 2025.